Literature DB >> 17721184

Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.

Maria Fernanda C Amary1, Patrick Pauwels, Els Meulemans, Guido M Roemen, Lily Islam, Bernadine Idowu, Konstantinos Bousdras, Timothy C Diss, Paul O'Donnell, Adrienne M Flanagan.   

Abstract

Desmoid-type fibromatosis is a locally aggressive deep soft tissue tumor. Some cases are associated with adenosis polyposis coli germline mutations whereas others harbor somatic beta-catenin point mutations mainly in exon 3, codons 41 and 45. These mutations result in stabilization of beta-catenin, and activation of the Wnt signaling pathway. The aim of this study was to determine the specificity and sensitivity of these 3 most common beta-catenin mutations in the diagnosis of desmoid-type fibromatosis using paraffin-embedded material. The results were compared with nuclear expression of beta-catenin. Mutation-specific restriction enzyme digestion methodology was employed to detect the 3 mutations. One hundred and thirty-three cases were analyzed, including 76 desmoid-type, and 18 superficial fibromatosis, in addition to a further 39 fibromatosis mimics. A restriction site was present for analysis of the codon 41 mutation. Mismatch primers were designed for the codon 45 mutations. Mutations were detected in 66 cases (87%) of 76 desmoid-type fibromatosis (71 extra-abdominal). Of these, 34 (45%) were in codon 45 (TCT>TTT), 27 (35%) in codon 41 (ACC>GCC), and 5 (7%) in codon 45 (TCT>CCT). No mutations were detected in the other lesions studied. All desmoid-type fibromatosis cases and 72% of the mimics tested showed nuclear positivity for beta-catenin indicating immunohistochemistry is a sensitive but not a specific test for desmoid-type fibromatosis. In contrast, to date, beta-catenin mutations have not been detected in any lesions which mimic desmoid-type fibromatosis. Mutation-specific restriction enzyme digestion, a simple and efficient means of detecting the common beta-catenin mutations in desmoid-type fibromatosis, complements light microscopy in reaching a diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721184     DOI: 10.1097/PAS.0b013e31802f581a

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  25 in total

1.  Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses.

Authors:  Sarah J Aitken; Nadège Presneau; Sangeetha Kalimuthu; Palma Dileo; Fitim Berisha; Roberto Tirabosco; M Fernanda Amary; Adrienne M Flanagan
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

2.  Prognostic factors in desmoid tumours: an example of translational oncology.

Authors:  Soledad Gallego Melcón
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

3.  Activity of Sorafenib against desmoid tumor/deep fibromatosis.

Authors:  Mrinal M Gounder; Robert A Lefkowitz; Mary Louise Keohan; David R D'Adamo; Meera Hameed; Cristina R Antonescu; Samuel Singer; Katherine Stout; Linda Ahn; Robert G Maki
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

Review 4.  The benefits of molecular pathology in the diagnosis of musculoskeletal disease : part I of a two-part review: soft tissue tumors.

Authors:  Adrienne M Flanagan; David Delaney; Paul O'Donnell
Journal:  Skeletal Radiol       Date:  2010-02       Impact factor: 2.199

5.  Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

Authors:  Shivaani Kummar; Geraldine O'Sullivan Coyne; Khanh T Do; Baris Turkbey; Paul S Meltzer; Eric Polley; Peter L Choyke; Robert Meehan; Rasa Vilimas; Yvonne Horneffer; Lamin Juwara; Ann Lih; Amul Choudhary; Sandra A Mitchell; Lee J Helman; James H Doroshow; Alice P Chen
Journal:  J Clin Oncol       Date:  2017-03-28       Impact factor: 44.544

6.  Pediatric craniopharyngioma in association with familial adenomatous polyposis.

Authors:  Nathan A Dahl; Drew Pratt; Sandra Camelo-Piragua; Chandan Kumar-Sinha; Rajen J Mody; Seth Septer; Todd C Hankinson; Arul M Chinnaiyan; Carl Koschmann; Lindsey Hoffman
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

Review 7.  Desmoid-Type Fibromatosis: Who, When, and How to Treat.

Authors:  Javier Martínez Trufero; Isabel Pajares Bernad; Irene Torres Ramón; Jorge Hernando Cubero; Roberto Pazo Cid
Journal:  Curr Treat Options Oncol       Date:  2017-05

8.  Sporadic, nontrauma-related, desmoid tumor of the pancreas: a rare disease-case report and literature review.

Authors:  F Polistina; G Costantin; E D'Amore; G Ambrosino
Journal:  Case Rep Med       Date:  2010-03-14

9.  β-Catenin mutation status and outcomes in sporadic desmoid tumors.

Authors:  John T Mullen; Thomas F DeLaney; Andrew E Rosenberg; Long Le; A John Iafrate; Wendy Kobayashi; Jackie Szymonifka; Beow Y Yeap; Yen-Lin Chen; David C Harmon; Edwin Choy; Sam S Yoon; Kevin A Raskin; Francis J Hornicek; Gunnlauger P Nielsen
Journal:  Oncologist       Date:  2013-08-19

10.  Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.

Authors:  Alexander J F Lazar; Daniel Tuvin; Shohrae Hajibashi; Sultan Habeeb; Svetlana Bolshakov; Empar Mayordomo-Aranda; Carla L Warneke; Dolores Lopez-Terrada; Raphael E Pollock; Dina Lev
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.